항체치료제 CDC (C1q Binding) Assay 서비스 | 고마바이오텍

특징 

• Complement-Dependent Cytotoxicity (CDC) assay로, Fc region을 보유한 항체의 기능을 확인하기 위한 분석입니다.
• 항체의 Fc 부위가 complement (보체) C1q와 결합하여 cancer cell을 lysis (cytotoxicity) 시킵니다. 
• C1q SPR binding assay는 항체의 Fc와 Human C1q사이의 결합력을 SPR을 이용하여 측정하는 서비스 입니다. 

Assay Information 

• Item: 730010
• Background Information: Complemental C1q is a subcomponent of C1 which is a key molecule for the progression of the proteolytic complement pathway involving in Fc-mediated mechanisms complement-dependent cytotoxicity (CDC). This binding assay between the Human C1q and the antibody/Fc fusion protein is performed with the Biacore 8K+ instrument.
• Family: Cell Surface (Other)
  
• Accession Number: P02745; P02746; P02747
  
• Organism: Human
  
• Construct Details: Full length, Purified
  
• Assay Type: Biochemical
  
• Assay Sub Type: Binding

• Procedure Summary:  The testing compound is captured onto the sensor chip as the ligand. Multiple concentrations of human C1q flow through the testing compound. SPR sensorgrams are fit to obtain the affinity (KD) between the testing protein and human C1q.
• Minimum for KD determination: 50 μl of 150 μM Antibody or Fc- fusion protein in PBS